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Abstract 
Background: Although accumulating evidence suggests that the crosstalk between malignant cells and cancer-
associated fibroblasts (CAFs) actively contributes to tumour growth and metastatic dissemination, therapeutic strate-
gies targeting tumour stroma are still not common in the clinical practice. Metal-based nanomaterials have been 
shown to exert excellent cytotoxic and anti-cancerous activities, however, their effects on the reactive stroma have 
never been investigated in details. Thus, using feasible in vitro and in vivo systems to model tumour microenviron-
ment, we tested whether the presence of gold, silver or gold-core silver-shell nanoparticles exerts anti-tumour and 
metastasis suppressing activities by influencing the tumour-supporting activity of stromal fibroblasts.
Results: We found that the presence of gold-core silver-shell hybrid nanomaterials in the tumour microenviron-
ment attenuated the tumour cell-promoting behaviour of CAFs, and this phenomenon led to a prominent attenua-
tion of metastatic dissemination in vivo as well. Mechanistically, transcriptome analysis on tumour-promoting CAFs 
revealed that silver-based nanomaterials trigger expressional changes in genes related to cancer invasion and tumour 
metastasis.
Conclusions: Here we report that metal nanoparticles can influence the cancer-promoting activity of tumour stroma 
by affecting the gene expressional and secretory profiles of stromal fibroblasts and thereby altering their intrinsic 
crosstalk with malignant cells. This potential of metal nanomaterials should be exploited in multimodal treatment 
approaches and translated into improved therapeutic outcomes.
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Background
Metastasis is considered as the most fatal hallmark of 
cancer, and the poor therapeutic outcome of patients 
diagnosed with invasive tumours illustrates its true 
gravity. Although many novel therapeutic strategies 
have recently been developed aiming to selectively kill 
malignant cells, accumulating evidence indicates that 
not only cancerous cells, but the cellular components 
of the reactive stroma should be targeted as well [1, 2]. 
The cellular composition of the tumour stroma is largely 
heterogeneous; fibroblasts, macrophages and other 
immune cells are the most frequent cancer-associated 
cell types in the tumour microenvironment [3]. Forma-
tion of a cancer-supporting milieu involves the recruit-
ment and concomitant conversion of various stromal 
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reciprocal crosstalk employing a multitude of secreted 
factors [4]. The most abundant non-cancerous cell popu-
lation within the reactive stroma is of cancer-associated 
fibroblast (CAF) as they might represent the 80% of the 
total tumour mass in pancreatic tumours [5]. The can-
cer-promoting activity of CAFs has been relatively well-
characterised, and it has been demonstrated that they 
interact with cancer cells during all stages of tumour 
development [6, 7]. The continuous and mutual informa-
tion exchange between CAFs and cancer cells supports 
the generation of the pre-metastatic niche, to which 
CAFs contribute primarily by secreting a plethora of 
growth factors, releasing tumour-stimulating exosomes, 
inducing epithelial-to-mesenchymal transition and neo-
angiogenesis, and by remodelling the components of the 
extracellular matrix [8–11]. Moreover, it has already been 
shown, that via various mechanisms, CAFs can promote 
the evolution of a multidrug-resistant tumour phenotype 
[12]. Many studies reported that pharmacological modi-
fication of the crosstalk between CAFs and tumour cells 
can hamper metastasis and ameliorate survival, further 
highlighting the supportive function of CAFs upon meta-
static dissemination [13–15].
In addition to small-molecular anti-cancer compounds, 
nano-sized materials represent promising alternatives 
in the development of novel therapeutic modalities 
[16]. Based on the unique physicochemical and biologi-
cal properties of nanoparticle systems, and owing to the 
simple and economical synthesis, the potential of metal 
nanoparticles in medicine is intensively investigated 
[17]. Various studies on in vivo and in vitro cancer mod-
els have reported that metal nanoparticles made of gold, 
silver, platinum, titanium or copper can effectively sup-
press tumour growth mainly by inducing apoptosis in 
cancer cells [18–21]. As an example, silver nanoparticle 
(AgNP) action on cancer cells—often referred to as a 
“Trojan-horse” type mechanism—encompasses cellu-
lar nanoparticle uptake, the subsequent release of reac-
tive ions and generation of a vast amount of reactive 
oxygen species, which ultimately target cellular macro-
molecules and organelles, altogether leading to the ini-
tiation of the apoptotic process [22]. Although this effect 
can be exploited in cancer treatment, it can also lead to 
systemic toxicity in non-target organs [23, 24]. In con-
trast, gold nanoparticles (AuNP) are considered to be 
relatively non-reactive and fairly biocompatible. Due to 
some singular physico-chemical characteristics, AuNPs 
have also been studied for therapeutic and diagnostic 
purposes [25]. Since they are capable of elevated photo-
electric absorption of radiation energy compared to soft 
tissues, these nanomaterials are recognised as excellent 
enhancers of radiotherapy [26]. In addition, gold nano-
particles are outstanding delivery platforms of cytotoxic 
drugs or therapeutic genes, which can ultimately be 
directed—rather selectively—into the microenvironment 
of the cancerous tissues, by exploiting the characteristic 
vascular abnormalities of solid tumours, often cited as 
enhanced permeability and retention effect (EPR) [27].
Although the direct impact of metallic nanoparticles 
on cancer cells is well-characterised, yet it is unknown 
how such nanoparticles would affect the reactive stroma, 
and in particular CAFs. Therefore, in this study, we 
investigated the behaviour and the tumour-promoting 
functions of CAFs upon metal nanoparticle exposures. 
In order to exploit the anti-cancer features of nanosil-
ver, but at the same time to attenuate its systemic toxic-
ity, as well as to profit from the biocompatible nature of 
gold nanoparticles, we generated a gold-core silver-shell-
structured hybrid nanoparticle system (Au@Ag) and 
tested their in vitro and in vivo performance, besides that 
of AgNPs and AuNPs. Our primary goal was to dissect 
the differences in biological effects exhibited by gold-
core silver-shell nanoparticles with those of only silver 
containing nanoparticles of the same size as Au@Ag, 
and secondly, to analyse the cellular response to AuNPs 
in order to model the potential impact of the gold core 
of the Au@Ag. Our broader aim was to explore, whether 
deploying gold- and silver-based nanoparticles in the 
tumour microenvironment would influence the cross-
talk between fibroblasts and cancer cells in such a way to 
improve tumour therapy outcome.
Results
AgNP and Au@Ag nanoparticles selectively inhibit 
adenocarcinoma cells
In order to obtain gold-core silver-shell nanoparticles, 
first, AuNPs had to be prepared using a chemical reduc-
tion method. The successful synthesis of AuNPs was 
verified by TEM and UV–Vis analysis (Additional file 1). 
The hydrodynamic diameter of the obtained AuNPs 
was approximately 8–9  nm. These AuNPs were used as 
seeds for the preparation of the citrate-stabilised gold-
core silver-shell Au@Ag nanoparticles, by establishing a 
covering silver layer. The larger size of Au@Ag (approx. 
11  nm) nanoparticles compared to AuNPs detected by 
DLS and TEM, and UV–Vis spectra characteristic to sil-
ver nanoparticles all indicated the successful synthesis of 
hybrid nanoparticles and verified the silver coverage of 
the gold surface. Finally, since we aimed to compare the 
performance of these hybrid nanoparticles with those 
of AgNPs, citrate-stabilised silver nanoparticles of the 
same size as Au@Ag nanoparticles (approx. 12 nm) were 
synthesised and subsequently characterised (Additional 
file 1).
To assess the cytotoxicity of the as-prepared silver-
containing nanoparticles, surviving curves and their 
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corresponding  IC50 values were determined upon 24  h 
AgNP and Au@Ag treatments on various adenocarci-
noma and fibroblast cell lines (Additional file  2a and 
Fig. 1a). Our results demonstrate, that Au@Ag nanopar-
ticles are considerably less toxic than AgNPs to all the 
applied cell lines. Furthermore, the obtained  IC50 values 
indicate that 4T1 and MCF-7 adenocarcinoma cells are 
more sensitive to both AgNP and Au@Ag nanoparticle 
treatments than non-cancerous NIH/3T3 and MRC-5 
fibroblast cells. The cytotoxicity of the AuNP nanoparti-
cles was also tested, however, on tumour cells no toxicity 
and on NIH/3T3 and MRC-5 fibroblast cells only minor 
cytotoxicity was detected (Additional file 2b). To further 
examine the impact of metal nanoparticles on the behav-
iour of healthy fibroblasts, wound healing experiments 
were performed on NIH/3T3 and MRC-5 fibroblasts and 
their migration capacities were tested. None of the nan-
oparticle treatments reduced the number of migrating 
fibroblasts (Additional file 3).
To mimic the milieu of the reactive stroma, fluores-
cently-labelled 4T1 adenocarcinoma cells were co-
cultured with non-labelled NIH/3T3 fibroblasts, then 
co-cultures were treated with AgNP or Au@Ag nanopar-
ticles in non-toxic concentrations (20 μM silver) or with 
AuNPs in concentrations corresponding to the amount of 
gold that the cells would receive over Au@Ag nanopar-
ticle treatments (25  μM gold). When co-cultures were 
exposed to either AgNP or Au@Ag nanoparticles, smaller 
tumour cell islands were observed by fluorescent micros-
copy compared to untreated co-cultures. Furthermore, 
flow cytometry revealed that the tumour cell/fibroblast 
ratio also decreased upon these nanoparticle treatments. 
On the other hand, gold nanoparticles did not influence 
the composition of the co-cultures (Fig. 1b, c).
Wound healing assays were performed on 4T1 and 
MCF-7 adenocarcinoma cells to assess the influence 
of metal-nanoparticles on cancer cell migration. While 
AuNPs did not inhibit wound closure, AgNP and Au@
Ag nanoparticles exhibited significant inhibitory action 
on both 4T1 and MCF-7 cells (Fig.  1d, e). Additionally, 
to ensure that the observed suppression in wound closure 
was not the result of activated apoptotic or necrotic 
pathways, cells were collected following wound heal-
ing assays, stained with Annexin V/Propidium iodide 
and the percentages of apoptotic and necrotic cells were 
quantified. The well-characterised apoptosis inducer 
12H-benzo[alpha]phenothiazine (M627) was used as 
a positive control (Additional file 4). None of the nano-
particle treatments triggered either apoptotic or necrotic 
cell death, indicating that the observed migration-sup-
pressing activity of Au@Ag and AgNPs is not coupled to 
cytotoxicity.
Finally, to test the potential inhibitory effect of the 
metal nanoparticle treatments on cell invasion, transmi-
gration capability of invasive 4T1 cells was investigated 
using Boyden chamber experiments. Gold nanoparticles 
did not suppress the invasion of 4T1 cells, while a signifi-
cantly reduced cell invasion was observed upon AgNP or 
Au@Ag nanoparticle exposures (Fig. 1f ).
Au@Ag nanoparticles inhibit metastasis in vivo
Since AgNPs and Au@Ag nanoparticles suppressed the 
proliferation and invasion of 4T1 cells in vitro, we tested 
the in vivo performance of these particles as well, using 
a 4T1 cell-based tumour model. For this, 4T1 cells were 
transplanted into the thoracic mammary fat pads of 
Balb/c mice, and when the tumours became palpable ani-
mals were divided into 4 groups to receive peritumoural 
injections of saline, AuNP, AgNP and Au@Ag nanoparti-
cles, respectively. Compared to saline obtaining animals, 
significant tumour growth inhibition was detected only 
in the Au@Ag receiving group at day 21 (P = 0.0392), 
which difference was strengthened when animals were 
dissected and tumour weights were measured at day 
23 (Fig.  2a, Additional file  5). This result indicates that 
among the three tested metal nanoparticles types only 
Au@Ag exhibited moderate, however noteworthy anti-
cancer activity in vivo.
Albeit we detected the above described anti-cancer 
effect of Au@Ag, unfortunately evaluation of possi-
ble metastasis suppressing activity of this nanoparticle 
was not possible under the applied conditions. Due to 
Fig. 1 AgNP and Au@Ag nanoparticles selectively inhibit breast adenocarcinoma cells. Breast cancer cells (4T1, MCF-7) and fibroblast cells (NIH/3T3, 
MRC-5) were treated with AgNP and Au@Ag nanoparticles, respectively, for 24 h then  IC50 values were calculated. AgNPs exerted higher cytotoxicity 
than Au@Ag nanoparticles, moreover, fibroblast cells were less sensitive to nanoparticle treatments than cancer cells (a). Fluorescently labelled 
4T1 tumour cells were co-cultured with unlabelled NIH/3T3 fibroblasts then treated with nanoparticles in non-toxic concentrations. Microscopic 
images (c) and flow cytometric evaluation of the co-cultures (b, c) revealed that AgNP and Au@Ag nanoparticle treatments reduced the ratio of 
cancerous cells in the tested co-cultures, while AuNP treatments did not influence the cellular composition of the samples (b, c). AgNP and Au@Ag 
nanoparticle treatments suppressed the wound healing activity of 4T1 and MCF-7 adenocarcinoma cells (d, e) demonstrated by cell free zones 24 h 
after scratching (d) and by quantitative evaluation of the wound healing activities (e). AgNP and Au@Ag nanoparticle treatments suppressed also 
the invasion of 4T1 adenocarcinoma cells (f). *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001; ****P ≤ 0.0001 indicate statistical significance (unpaired t-test)
(See figure on next page.)
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the high number of transplanted 4T1 cells the primary 
tumours grew fast and the animals had to be terminated 
according to animal handling rules and regulations before 
the metastatic tissue in the lungs could be developed 
reaching the threshold of statistical evaluation. As our 
main interest was to delineate the metastasis modulating 
ability of these nanomaterials, therefore, we performed 
a second in  vivo experiment with modified conditions. 
Since among the previously tested nanoparticles only 
Au@Ag exhibited measurable anti-tumour activity, in 
this second in  vivo experiment we employed Au@Ag 
nanoparticles either alone or together with intravenously 
administrated doxorubicin to test concomitantly how 
these hybrid nanoparticles would perform in combina-
tion with an anti-cancer drug already utilized in clini-
cal practice. In line with these, tumour-bearing animals 
were treated with either Au@Ag alone, or in combina-
tion with doxorubicin, and with their respective admin-
istration controls (Fig. 2b). The desired moderate tumour 
progression rate was achieved, granting a notably longer 
experimental period for the development of measurable 
metastatic lesions. The animals received four treatments 
over 12 days, then were left untreated for further 2 weeks 
before they were euthanized. After the last treatments at 
day 12, significantly smaller tumour sizes were detected 
both in Au@Ag-exposed as well as in Au@Ag + doxoru-
bicin receiving animals (Fig. 2c, Additional file 6a). More 
importantly, the metastatic mass in the lungs (Fig.  2c), 
the number of surface metastatic nodules (Additional 
file 7) and also the extent of the metastatic area (Fig. 2d,e, 
Additional file  6b) were significantly decreased in both 
Au@Ag nanoparticle receiving groups compared to the 
control animals. These findings indicate that Au@Ag 
nanoparticles attenuate metastasis.
Additionally, according to an obligatory protocol, a 
standard toxicology experiment was performed where 
Balb/c mice obtained intravenous Au@Ag injections 
four times, then essential toxicological parameters were 
Fig. 2 Au@Ag nanoparticles suppress metastasis in vivo. To test the in vivo activity of AgNP, AuNP and Au@Ag nanoparticles, 4T1 cells were 
transplanted into the mammary fat pad of Balb/c mice, then animals were divided into 4 groups (n = 6/group). Animals received nanoparticles 
peritumourally four times, and tumour sizes were repeatedly measured throughout the experimental period. Au@Ag nanoparticle treatments 
resulted in a significant suppression of 4T1 tumour growth (a). To investigate the anti-metastatic activities of Au@Ag nanoparticles, lower number 
of 4T1 cells were inoculated into the mammary fat pads of Balb/c mice then animals were divided into 5 groups (n = 6–7/group) to receive Au@
Ag nanoparticles alone or in combination with doxorubicin. We found that Au@Ag alone and also in combination with doxorubicin hampered 
tumour progression significantly (b). After the last treatment (on day 12), animals were left untreated for further two weeks to let the metastatic 
lesions in the lungs grow to a potentially detectable level. On day 28 animals were euthanised and lungs were dissected. Au@Ag treatments alone 
and in combination with doxorubicin reduced the mass of metastatic tissue in the lung of the animals (c). Histopathology of the lung specimen 
also confirmed the anti-metastatic efficiency of Au@Ag, since the area of the metastatic lesions was significantly lower in nanoparticle-treated mice 
(c–e). *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001 indicates statistical significance (unpaired t-test)
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determined. Au@Ag treatments did not influence either 
body weight or the weight of the animals’ liver or spleen, 
indicating no systemic toxicity of the applied treatments 
(Additional file 8).
Metal nanoparticles suppress cancer‑promoting activity 
of tumour‑associated fibroblasts
We found that the remarkable in  vivo metastasis-sup-
pressing capability of Au@Ag nanoparticles was not 
coupled to a strong primary tumour growth inhibition, 
suggesting that nanoparticles affect notably the metas-
tasis-promoting cells in the reactive stroma. Histopa-
thology data on in  vivo 4T1 tumours show recruitment 
of massive amounts of host-derived fibroblasts into the 
tumour microenvironment (data not shown). As cancer-
associated fibroblasts represent the largest portion of 
the reactive tumour stroma, we decided to investigate 
further whether metal nanoparticle treatments influ-
ence the metastasis-promoting activity of the tumour 
microenvironment.
To this, we established in vitro co-culture systems using 
mouse NIH/3T3 fibroblasts and 4T1 adenocarcinoma 
cells and also, a similarly arranged human model system 
using patient-derived primary CAFs (characterised in 
Additional file  9) and MCF-7 human adenocarcinoma 
cells. In these co-culture systems, confluent fibroblast 
layers were cultured on the surface of 0.4 μm pore sized 
transwell inserts, while adenocarcinoma cells were grown 
in the lower chamber and their migration activity was 
monitored by wound healing assays (Fig.  3a). Fibro-
blasts and tumour cells were co-cultured for 24 h, then in 
order to selectively expose tumour-associated fibroblast 
cells nanoparticles were added to the upper chamber in 
non-toxic concentrations (20  μM silver or/and 25  μM 
gold, respectively). Concomitantly to the addition of the 
nanoparticles, wounds were scratched into the confluent 
layer of adenocarcinoma cells in the lower chamber, and 
24 h later the sizes of the cell-free zones were evaluated 
to assess wound healing activities of 4T1 or MCF-7 cells, 
respectively (Fig. 3b, c).
In the presence of both NIH/3T3 and patient-derived 
cancer-associated fibroblast cells, tumour cell migration 
increased significantly, supporting that the attendant 
fibroblast cells promote the motility of adenocarcinoma 
cells. AgNP and Au@Ag treatments significantly sup-
pressed the tumour cell-promoting activity of fibroblasts, 
which feature manifested in reduced wound closure, thus 
slower migration of adenocarcinoma cells. In contrast, no 
differences in cancer cell migration ability were observed 
when AuNPs were present in the co-cultures. At the end 
of each experiment, fibroblast containing inserts were 
stained with crystal violet and were inspected to ensure 
that confluent cell layers remained intact throughout the 
treatment, so nanoparticles could not diffuse through 
the membrane into the lower chamber (data not shown). 
Also, to exclude the possibility that nanoparticles pro-
voke fibroblast membrane damage resulting ultimately in 
cell membrane leakage, NIH/3T3 fibroblasts were treated 
with AuNP, AgNP and Au@Ag nanoparticles (in 20 μM 
silver or/and 25 μM gold concentrations), and 24 h later 
lactate dehydrogenase (LDH) activity was measured in 
the supernatant (Additional file 10).
As the LDH activity was not elevated in the superna-
tant of nanoparticle treated fibroblasts compared to 
untreated cells, we assumed that the previously observed 
tumour cell proliferation-modulatory effects of fibro-
blasts must be the result of the altered secretory profiles 
and not of cell membrane-leaking factors. To further 
verify that nanoparticle treatments can modify the secre-
tory profile of fibroblasts and thereby the cancer cell-
supporting function of these stroma cells can be altered, 
NIH/3T3 and patient-derived CAF cells were exposed 
to nanoparticles, then nanoparticle containing media 
were replaced by serum-free media in order to collect 
fibroblast-secreted factors. The obtained conditioned 
media were concentrated, and applied on 4T1 or MCF-7 
adenocarcinoma cells for 24  h, then cell migration was 
monitored by wound healing assay (Fig. 3d, e). Addition 
of untreated fibroblast-derived conditioned media to the 
adenocarcinoma cells increased cell migration signifi-
cantly. A comparably elevated migration was observed 
when 4T1 or MCF-7 were exposed to media collected 
from AuNP-pre-treated fibroblasts. More importantly, 
when conditioned media of either AgNP- or Au@Ag 
Fig. 3 AgNP and Au@Ag treatments modulate the tumour-promoting activity of cancer-associated fibroblasts. To analyse whether nanoparticle 
treatments can affect the tumour-promoting activity of CAFs, first, a co-culture system was established in which 4T1 or MCF-7 tumour cells were 
grown in the lower chambers and NIH/3T3 or primary CAF cells were cultured separately in the upper compartments of 0.4 μm pore-sized transwell 
inserts (a). Wound healing activity of 4T1 or MCF-7 cells was monitored after selective treatment of NIH/3T3 or CAF fibroblast cells with non-toxic 
concentrations of metal nanoparticles. Experiments revealed that AgNPs and Au@Ag nanoparticles disrupted the fibroblast-induced, elevated 
wound healing activity of both 4T1 (b) and MCF-7 (c) cells. Similar experiments were performed using the conditioned media of AgNP, AuNP or 
Au@Ag nanoparticle-pre-treated NIH/3T3 and primary CAF cells. When adenocarcinoma cells were treated with the fibroblast-conditioned media, 
cell-free zones were scratched to the confluent cancer cell layers, then the area of the cell free zones were measured 24 h later to calculate wound 
healing activity. AgNP and Au@Ag treatments decreased the wound healing-promoting activity of both NIH/3T3 (d) and primary CAF cells (e). 
*P ≤ 0.05; ***P ≤ 0.001; ****P ≤ 0.0001 indicates statistical significance (unpaired t-test).
(See figure on next page.)
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nanoparticle-pre-treated NIH/3T3 or primary human 
fibroblasts were applied on cancer cells, the tumour cell-
promoting effects of the fibroblast-derived media dimin-
ished, resulting in a comparable migration activity as 
non-stimulated counterparts. A similar experiment was 
performed using BrdU incorporation assay as a read-out 
to measure cell proliferation. The results obtained from 
the BrdU assays, validated all the previously observed 
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attenuating effects of metal nanoparticles on the cancer 
cell migration-promoting effects of fibroblasts (Addi-
tional file 11).
To demonstrate that these fibroblast-modulating 
effects of metal nanoparticles can be observed not only 
in cell culture, but also in vivo, we performed immuno-
histochemistry on the tumour samples obtained from 
mice treated with Au@Ag nanoparticles (tumours from 
animals in experiment shown on Fig. 2b–e). Tumour sec-
tions were counterstained with an antibody recognising 
the CAF marker alphaSMA-, as well as with proliferation 
marker Ki67-specific  antibodies (Fig.  4a). Subcutaneous 
tumour regions were photographed and fibroblast-rich 
and fibroblast-poor fields were analysed. We observed 
higher number of Ki67-positive tumour cells within 
the fibroblast-rich regions, whereas cancer cells within 
tumour zones infiltrated with lower numbers of CAF 
cells were less proliferative (Additional file 12). Although 
this observation shows that CAF cells and proliferat-
ing tumour cells are embedded in the same niche of the 
tumour tissue, it also suggests that the presence of host-
derived CAF cells promote the proliferation activity of the 
xenografted 4T1 cells. Most importantly, when tumours 
were treated with Au@Ag nanoparticles, a reduced num-
ber of Ki67-positive tumour cells were identified in the 
fibroblast-rich microdomains. To strengthen this lat-
ter observation, we analysed 4–5 photographs of each 
tumour sample in identical anatomical regions, and the 
relationship between Ki67- and alphaSMA-positive cells 
was tested by Pearson correlation test. A strong positive 
correlation between Ki67- and alphaSMA-positive cell 
density was found in saline-treated tumours (Fig. 4b). In 
the Au@Ag nanoparticle-treated tumours a lower Ki67-
positive cell density was identified, whereas no change 
was observed in the number of alphaSMA-positive 
fibroblasts (Additional file 13). Hence, the nanoparticle-
induced modulation of the tumour microenvironment 
resulted in a loss of positive correlation between cancer-
associated fibroblasts and proliferative tumour cells. This 
observation suggests that Au@Ag nanoparticles suppress 
the cancer cell proliferation-promoting activity of CAF 
cells not only in vitro, but in vivo as well.
AgNP and Au@Ag nanoparticles trigger expressional 
changes in metastasis‑related genes
To reveal the possible mechanisms behind the altered 
behaviour of cancer-associated fibroblasts which were 
induced by metal nanoparticle exposures, we selectively 
treated NIH/3T3 fibroblast cells with AuNP, AgNP and 
Au@Ag nanoparticles in our co-culture model (as in 
Fig. 3a), then total RNA was isolated from the fibroblast 
cells and was used to perform RNA-seq. AuNPs did not 
trigger notable gene expressional changes, while AgNP 
and Au@Ag treatments induced significant alterations 
in the transcriptome of cancer-associated fibroblast cells. 
The gene expression changes produced by AgNP and 
Au@Ag nanoparticles seem largely similar (Fig. 5a, Addi-
tional files 14, 15). It is also noteworthy that both AgNP 
and Au@Ag provoked the highest fold changes in met-
allothionein (Mt1, Mt2) and heme oxygenase (Hmox1) 
expressions.
Fig. 4 Au@Ag treatments decrease the number of proliferating cancer cells in fibroblast-rich tumour microdomains. High number of Ki67-positive 
cells can be identified in the alphaSMA-positive fibroblast-rich microdomains in saline-treated 4T1 tumours, while the number of proliferating 
tumour cells is markedly lower in the Au@Ag-treated tumours (a). In saline-treated tumours, a positive correlation can be identified between 
the numbers of Ki67- and alphaSMA-positive cells indicating that there is a noticeably higher proliferation activity in the fibroblast-rich regions 
of the cancerous tissue. On the other hand, loss of the positive correlation between Ki67- and alphaSMA-positive cells can be identified in Au@
Ag-treated tumours, since the nanoparticle treatment decreased the number of Ki67-positive cells without influencing the number of infiltrated 
cancer-associated fibroblasts (b)
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To identify specific differences between the transcrip-
tomic profiles of AgNP- and Au@Ag-treated cells and to 
link the obtained expressional changes to biological func-
tions, gene ontology analysis was performed with the list 
of up- and downregulated genes using Panther-GO slim 
Biological Processes statistical overrepresentation test 
and Panther Pathways analysis. Regarding the repressed 
genes, statistically significant enrichment was observed 
in cell cycle- and cell division-related Gene Ontology 
groups, implying that both AgNP and Au@Ag nanopar-
ticle treatments triggered cell cycle arrest in fibroblasts 
(Fig. 5b). Interestingly, significant enrichment in cellular 
component movement GO group was observed solely 
in Au@Ag nanoparticle-treated cells. As of upregulated 
genes, AgNP treatments induced the expression of genes 
belonging to cell death-related ontology groups, while 
these GO groups did not show significant enrichment 
upon Au@Ag exposures. Both AgNP and Au@Ag nano-
particle treatments led to statistically significant enrich-
ments in endoderm development gene ontology group. 
More importantly, according to our transcriptome analy-
sis, AgNPs activated oxidative stress response, apoptosis, 
and toll receptor-related signalling pathways, while Au@
Ag nanoparticle treatments induced the expression of 
genes related to the p53 pathway (Fig. 5b).
Among the significantly up- and downregulated 
genes, we identified 11 hits, where the gene products 
are secreted by fibroblasts and have already been linked 
to cancer invasion and tumour metastasis (Fig.  5c, 
Table  1). From our transcriptome analysis four genes—
presenting the most remarkable expressional suppres-
sion upon nanoparticle treatments [Spp1 (Osteopontin), 
Ptn (Pleiotrophin), Thbs2 (Thrombospondin 2), Adamts5 
(ADAM metallopeptidase with thrombospondin type 
1 motif 5)]—were selected to evaluate whether a cor-
relation between the altered expression level of these 
genes and cancer patient survival can be identified. For 
this analysis clinical data of a 3951 breast cancer cohort 
was used. Kaplan Meier-plots generated for the chosen 
genes revealed that high expression of Spp1 reduced 
significantly breast cancer patient survival, indicating 
the clinical relevance of intratumoural Osteopontin lev-
els (Fig.  5d, Additional file  16). Using gene expression 
data available at TCGA database of patients diagnosed 
with breast cancer and of matching healthy samples, we 
found that among the identified 11 hits Spp1 (Osteo-
pontin) shows the highest tumour-specific upregula-
tion (Fig. 5e, Additional file 17). Furthermore, analysis of 
reported expression data on metastatic sub-populations 
of 4T1 breast cancer revealed that elevated Spp1 expres-
sion is associated to lung, bone and liver-specific meta-
static activity as well (Fig.  5f ). This evidence supports 
that (i) Spp1 expression is upregulated in breast cancer, 
(ii) it is linked to metastasis and (iii) its high expression 
is coupled to poor patient survival. Thus, the molecular 
mechanisms modulating Spp1 expression for example 
by nanoparticle administration are fundamentally inter-
twined with therapy outcome and life expectancy. Based 
on these findings we examined in vivo whether Au@Ag 
nanoparticle treatments would lead to decreased expres-
sion of Spp1. Using western blot analysis, we quantified 
the intratumoural levels of Osteopontin as well as of the 
fibroblast markers alphaSMA and Vimentin in the Saline- 
and Au@Ag-treated 4T1 tumour samples (Fig.  5g) (in 
tumours obtained from animals in experiment shown on 
Fig.  2b–e). Densitometrical analysis revealed that while 
Au@Ag treatments did not influence the intratumoural 
protein levels of the fibroblast markers alphaSMA and 
Vimentin, these nanoparticles significantly reduced 
Osteopontin expression in the metastatic 4T1 tumours 
(Fig. 5h).
Discussion
In the last decade, owing to the unique biological fea-
tures, like antibacterial, antiviral and antifungal activi-
ties, metal nanoparticles, especially AgNPs have gained 
Fig. 5 AgNP and Au@Ag treatments induce similar transcriptomic changes in CAFs. In order to reveal potential mechanisms in the background 
of the tumour modulatory effects of CAFs, NIH/3T3 fibroblasts—co-cultured with 4T1 tumour cells—were treated with nanoparticles then 
transcriptome analysis was performed. Heat map showing the observed gene expressional changes indicates that AgNP and Au@Ag nanoparticle 
treatments induced similar transcriptomic profiles, with significant transcriptomic alterations in several hundred genes (a). Gene ontology analysis 
of repressed and induced genes as well as of upregulated pathways was performed to link the observed transcriptomic changes to biological 
functions. Both AgNP and Au@Ag nanoparticles repressed the transcription of cell cycle- and cell division-related genes, however, only AgNPs 
induced cell death-associated gene expressional changes (b). Among the repressed and upregulated genes, several genes have secreted protein 
products which are related to cancer metastasis. AgNP and Au@Ag nanoparticle treatments decreased the majority of these metastasis-related 
genes in cancer associated fibroblasts (c). Kaplan–Meier plot of breast cancer patients with low and high Spp1 expression indicates that the 
elevated expression of Spp1 significantly worsens the survival of patients highlighting the clinical significance of intratumoural Osteopontin levels 
(d). TCGA patient data indicates that Spp1 expression is upregulated in breast cancer (e). Elevated Spp1 expression is associated to metastasis in 
4T1 tumour model (f). Au@Ag treatments do not influence the expression levels of CAF markers alphaSMA and Vimentin, while significantly reduce 
intratumoural Osteopontin expression in vivo (g, h). Full-length blots are presented as Additional file 18
(See figure on next page.)
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enormous attention. Since the anti-cancer effects of sil-
ver nanoparticles have been proposed, an even greater 
impetus was given to demonstrate the applicability of 
these nanomaterials in cancer treatment. However, the 
de facto application of AgNPs in oncotherapy is fraught 
with limitations, for example by some undesired 
effects to non-cancerous cells [28]. In contrast, gold 
nanoparticles are fairly biocompatible, therefore they 
hold considerable therapeutic potential for future clini-
cal applications. In view of these established features 
i.e. the prominent anti-cancer effects of silver nanopar-
ticles and the biocompatible nature of gold nanomate-
rials, we generated a hybrid nanoparticle system and 
examined its modulatory effects on cancer cells as well 
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as on the tumour-promoting features of cancer-associ-
ated fibroblasts.
AgNPs are generally considered to be toxic to living 
organisms limiting their utilisation in cancer therapy. 
Using in vitro and in vivo approaches, we identified sev-
eral favourable properties and actions of Au@Ag nano-
particles over AgNPs. For instance,  IC50 values indicated 
that Au@Ag nanoparticles were less cytotoxic toward 
all of the examined adenocarcinoma and non-cancerous 
fibroblast cells compared to AgNP nanoparticles, albeit 
being similarly cancer cell-specific. Further advantages 
of Au@Ag nanoparticles were also apparent when migra-
tion-inhibitory and cell-invasion modulating activities 
of sub-cytotoxic doses of Au@Ag and AgNP nanoparti-
cles were tested. In this respect the performance of the 
less-toxic Au@Ag nanoparticles was again comparable to 
those of the more-toxic AgNP counterparts. Concomi-
tantly, in  vivo toxicology experiment verified that intra-
venous administration of Au@Ag nanoparticles displayed 
no systemic toxicity in mice. Importantly, the size-surface 
ratio of the applied AgNPs were comparable to that of 
Au@Ag particles, hence showing different cytotoxicity. 
We believe that such a difference presumably results as 
a consequence of different Ag ion releasing dynamics. It 
is well-known that the reactive silver ions released from 
the nanoparticle surface are responsible for the major-
ity of the biological effects of silver-based nanomateri-
als, therefore larger differences in this chemical property 
can undoubtedly influence the in vitro and in vivo toxic-
ity of the tested nanoparticles. It has been reported that 
AgNPs are not able to dissolve completely but they can 
become passivated after releasing a given amount of ions, 
resulting in an inactive core, which cannot release reac-
tive ions anymore [29]. These remnants can accumulate 
in the body and can therefore induce either short-term or 
long-term adverse effects. A possible explanation for the 
lower toxicity of Au@Ag might be the lack of accumula-
tion of such ultra-small silver nanoparticle remnants, 
instead, a biocompatible non-toxic gold core remains 
behind after Au@Ag action. Nevertheless, to verify this 
hypothesis further investigation is required.
After demonstrating the rationality and the suitability 
of using core–shell structured Au@Ag nanoparticles, we 
wanted to test whether the presence of such nanoparti-
cles in the tumour microenvironment could as well influ-
ence the metastatic potential of the primary tumours. 
Since the nanoparticles applied throughout the experi-
ments were not optimized for a sustained plasma stabil-
ity, therefore we bypassed the reticuloendothelial system 
by administrating the nanoparticles directly into the 
tumour microenvironment. Interestingly, administrated 
Au@Ag nanoparticles within the tumour tissue inhibited 
4T1 tumour growth only mildly, but a striking suppres-
sion in the metastatic activity of the primary tumours 
could be observed in the nanoparticle-treated animals. 
This observation suggests that the outstanding anti-met-
astatic activity of the Au@Ag nanoparticles is not linked 
to a strong tumour growth inhibitory potential. The fact 
that the two features (metastasis suppression and tumor 
growth inhibition) do not change concomitantly, can-
not be considered unusual. Indeed, using the same 4T1 
tumour metastasis model, Avgustinova et  al. [30] found 
that the lack of activation of cancer-associated fibroblasts 
by Wnt7a led to a loss of metastatic potential which was 
Table 1 Functions of cancer-associated genes showing expressional changes in CAFs upon AgNP and Au@Ag exposures
Hit Protein product Role in invasion and metastasis References
Spp1 Osteopontin Promotes metastasis and invasion [42–44]
Ptn Pleiotrophin High Ptn expression is correlated with metastasis, regulates 
cancer cell migration
[45]
Thbs1 Thrombospondin-1 Deregulation of Thbs1 promotes tumour angiogenesis and 
metastasis
[46, 47]
Col6a1 Collagen type VI alpha 1 chain Col6a1 expression is associated with tumour size and metas-
tasis
[48, 49]
Col6a2 Collagen type VI alpha 2 chain High Col6a2 expression is correlated with poor cancer survival [50]
Ccl7 chemokine (C-C-motif ) ligand 7/monocyte-chemotactic 
protein 3
Tumour-associated fibroblast-driven CCL7 promotes metas-
tasis
[51, 52]
Thbs2 Thrombospondin-2 Cancer cell-derived Thbs2 induces fibroblast activation. Thbs2 
promotes bone metastasis in prostate cancer
[53, 54]
Adamts5 ADAM metallopeptidase with thrombospondin type 1 motif 5 Adamts5 overexpression regulates invasion of non-small cell 
lung cancer
[55, 56]
Cyr61 Cystein rich angiogenic inducer 61 Promotes tumour cell extravasation and metastasis [57]
Ctgf Connective tissue growth factor Promotes osteosarcoma angiogenesis [58]
Mmd Monocyte to macrophage differentiation protein Regulates tumour growth in non-small cell lung cancer [59]
Page 12 of 20Kovács et al. J Nanobiotechnol           (2020) 18:18 
not coupled to a reduced in  vivo tumour growth. Since 
we found the same phenotype on Au@Ag treated mice, 
we speculated that these nanoparticles, apart from the 
observed direct effects on cancer cells, could also mod-
ulate the behaviour of metastasis-promoting stromal 
fibroblasts. This hypothesis prompted us to install an 
in vitro co-culture system in which the indirect effects of 
the nanoparticle treatments could be monitored. In the 
established co-culture models, CAF cells clearly mani-
fested tumour cell-promoting characteristics, which were 
effectively counter-modulated by AgNP and Au@Ag nan-
oparticles. As the nanoparticle treatments did not trigger 
fibroblast cell death or membrane leakage, we presumed 
that an alteration in the secretory profile of the cancer-
promoting fibroblasts was triggered by the applied 
nanomaterials. This theory was further strengthened by 
treatments with conditioned media derived from nano-
particle-exposed fibroblasts, which provoked a similar 
effect on the adenocarcinoma cells as was previously seen 
by direct exposures of the co-cultures to nanoparticles.
When tumours of mice treated with Au@Ag were 
examined, reduced numbers of proliferative cancer cells 
were found in the fibroblast-rich microenvironment. This 
attenuated proliferation of cancer cells within the fibro-
blast-abundant tumour microdomains further supports 
the concept that Au@Ag nanoparticles affect cancer cells 
both directly as well as indirectly via modulation of stro-
mal fibroblast cells. However, it should also be mentioned 
that Au@Ag nanoparticle treatments don’t seem to influ-
ence the capability of cancer cells to recruit CAF cells, as 
we found comparable levels of intratumoural fibroblasts 
in Saline- and Au@Ag-exposed animals by histopatho-
logical evaluation and by western blotting.
In our quest to identify potential cellular components 
targeted by nanoparticles in cancer-associated fibro-
blasts and to reveal mechanistic details on the effects 
of nanoparticle treatments on CAF cells, we performed 
transcriptome analysis. To our knowledge these are the 
first reported RNA-seq data sets on metal nanoparti-
cle-treated cancer-associated fibroblasts. The analysis 
revealed that several secreted factors already linked to 
cancer metastasis showed repressed expression upon 
metal nanoparticle treatments. Growth factors (e.g. 
Spp1, Ptn), cytokines (CCl7, Mmd), extracellular compo-
nents and extracellular matrix modifying factors (Thbs1, 
Col6a1 and Col6a2 and Adamts5) were identified in 
the transcriptomic background of the modified fibro-
blast behaviour in our co-cultures. These findings sup-
port the idea that alterations in the secretory profiles of 
nanoparticle-exposed cancer-associated fibroblasts are 
responsible for the observed modulatory effects of CAF 
cells. More importantly, these factors might also serve 
as therapeutic targets in future developments aiming 
the tumour stroma, and for this purpose, their precise 
function in tumour cell—fibroblast crosstalk should be 
investigated. Using metadata analysis of clinical cohorts, 
reported datasets and TCGA patient data extraction, we 
identified Spp1 as a particularly promising target, since 
the high expression of this gene in breast cancer patients 
is coupled to poor patient survival and metastasis. More-
over, our data on 4T1 challenged mice also indicated that 
Au@Ag treatments decrease the intratumoural expres-
sion of this novel cancer-related metastasis-promoting 
therapeutic target in vivo.
The whole transcriptome profiles of metal nano-
particle-treated cancer-associated fibroblast cells also 
reflected that AgNPs and Au@Ag nanoparticles induced 
mostly expressional changes of genes related to cell cycle 
and cell division, suggesting that such nanoparticles exert 
an anti-proliferative effect in this cell type. On the other 
hand, AgNPs induced cell death- and apoptosis-associ-
ated transcriptomic alterations, whereas Au@Ag nano-
particles did not trigger the expression of such genes, 
which notion further corroborates the better cytocom-
patibility of the hybrid nanoparticles over AgNPs. This 
observation supports the hypothesis that while AgNPs 
can likely release Ag ions rapidly, the release of toxic 
ions from the gold core can potentially be slower or less 
effective, resulting in a sustained and prolonged anti-
proliferative effect of Au@Ag treatments. It is also note-
worthy, that nanoparticle treatments did not modify the 
expression of CAF and myofibroblast marker genes (e.g. 
alphaSMA, Vimentin) implying that unlike other nano-
materials (e.g. carbon nanotubes [31]), our metal nano-
particles do not influence fibroblast differentiation.
AuNPs (the same particles used as seeds for the 
core–shell nanoparticle synthesis) were systematically 
applied in parallel experiments throughout the entire 
study and their effects were constantly monitored. This 
was done with the purpose to estimate the individual 
contribution of the gold-core part to the biological 
effects exerted by Au@Ag nanoparticles and to analyse 
the behaviour of both in  vivo and in  vitro models to 
gold exposures. Similarly to AgNPs and Au@Ag nano-
particles, AuNPs were also readily taken up by both 
adenocarcinoma and fibroblast cells, revealed by TEM 
analysis (data not shown). Surprisingly, upon treat-
ments with AuNPs, we did not observe significant tox-
icity or anti-tumoural actions which, however, can be 
explained by the biocompatible, biologically inert fea-
tures of citrate-coated gold-materials. This finding is 
in a good accordance with several recent observations, 
where the authors reported the lack of AuNP toxicity 
toward various fibroblast cells [32, 33]. On the other 
hand, some publications presented results showing that 
gold nanoparticles are able to trigger anti-tumoural 
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effects, can suppress metastasis and reverse epithelial-
to-mesenchymal transition in melanoma [34]. Further-
more, Zhao et  al. [35] reported recently, that in their 
study AuNPs could reduce intratumoural fibroblast 
density, and enhanced the efficacy of cisplatin-based 
chemotherapy. These controversial results demonstrate 
that key physico-chemical properties of AuNPs, such as 
size, surface charge and capping materials can dramati-
cally influence the behavior and feasibility of metallic 
nanoparticles. In our transcriptome analysis we did 
not observe significant gene expressional differences 
between control and AuNP-exposed fibroblasts, sug-
gesting a lack of notable response from CAFs to gold 
exposures. However, this latter observation could also 
be explained by the resolution of the performed RNA-
seq, which allowed only the markedly expressed genes 
to be involved in the analysis, and therefore, it can-
not be excluded that AuNPs induced some changes in 
genes with low basal expression.
Nevertheless, the intracellular presence of the gold-
core of Au@Ag nanoparticles can yield ultimate ben-
efits. Since, in accordance with the literature [36], and 
based on our own observations (data not shown) the 
gold-cores of Au@Ag nanoparticles possess strong 
radiosensitising effect in cancer cells, which feature can 
be excellently exploited in radiotherapy. As a result, we 
assume that while the dissociative silver-shell can be 
considered as the active anti-cancer component, after 
the silver shell completely vanishes due to silver ion 
release, the residual gold-core in the tumour microen-
vironment could serve to enhance the efficiency of radi-
otherapy. This 2-in-1 formulation renders such Au@
Ag core–shell nanostructures particularly attractive 
platforms for the development of clinically applicable 
therapeutic agents.
Finally, as in the clinical practice chemotherapy is real-
ised mainly in a combinational manner, we investigated 
the suitability and the performance of locally admin-
istrated Au@Ag nanoparticles in combination with 
intravenous doxorubicin treatments. We found that the 
in  vivo metastasis-suppressing activity of Au@Ag was 
maintained upon combinational doxorubicin administra-
tions, and simultaneously, the most significant reductions 
in tumour sizes were observed by doxorubicin + Au@Ag 
nanoparticle-treated animals. This is a highly relevant 
finding, as it demonstrates that the powerful anti-meta-
static and anti-cancer effects of Au@Ag are not compro-
mised when another antineoplastic drug is introduced, 
and it emphasises the excellence of Au@Ag nanoparticles 
as combinational partners in chemotherapy. Hence we 
believe that core–shell Au@Ag nanoparticles hold excep-
tional potential in advanced oncotherapy approaches as 
chemotherapy adjuvants.
Conclusions
In summary, this study provides compelling data on the 
suitability and in vitro and in vivo efficacy of gold-core 
silver-shell type nanoparticles as potent anti-metastatic 
and anti-cancer agents. Besides their low toxicity, we 
also demonstrate that Au@Ag nanoparticles achieve 
the outstanding metastasis-suppressing activity by (i) 
acting directly on adenocarcinoma cells via inhibiting 
their proliferation, (ii) as well as indirectly by affect-
ing cancer-associated fibroblasts through attenuating 
their cancer-promoting capabilities and modulating 
their secretory profiles. Au@Ag nanoparticles, applied 
alone or in combination with other chemotherapeutic 
agents, exert potent anticancer capability due to the 
dissociative silver-shell, whereas the residual gold-core 
could serve to amplify the effects of radiation therapy. 
Considering the moderate success rate of conventional 
chemotherapy and frequent cancer reoccurrence, utili-
sation of Au@Ag nanoparticles could provide numer-
ous advantages in multimodal treatment approaches.
Methods
Nanoparticle synthesis and characterisation
All chemicals applied upon the synthesis of the nano-
materials were purchased from Sigma-Aldrich. Citrate-
stabilised silver nanoparticles (AgNP) were synthesised 
by chemical reduction using sodium borohydride. 
First 0.2  g of sodium citrate was dissolved in 75  mL 
deionised water with vigorous stirring. The solution 
was heated to 70 °C and 2 mL of 1 m/V% silver nitrate 
 (AgNO3), then 2 mL of 0.1 m/V%  NaBH4 solution was 
added drop-wise into the mixture. The resulting yellow-
ish-brown suspension was stirred on 70 °C for an hour. 
The final colloid samples were stored at 4  °C. Citrate-
stabilised gold nanoparticles (AuNP) were synthesised 
by a similar process as AgNP nanoparticles except that 
tetrachloroauric acid solution was used as initial gold 
source.
The gold-core silver-shell nanoparticles were obtained 
using a method previously reported [37]. The formerly 
produced gold nanoparticle suspension was used as a 
seed solution and the silver-shell was established by 
multiple rounds of silver ion reduction. First, 60  μL of 
l-ascorbic acid solution (100  mM), 15  μL of  AgNO3 
(100  mM), and 75  μL of sodium hydroxide (NaOH, 
100 mM) were added to a beaker containing 10 mL of the 
as-prepared AuNPs at room temperature and pH = 8.5. 
The reaction was slowly stirred for 30 min before 60 μL 
of l-ascorbic acid (100 mM), 15 μL of  AgNO3 (100 mM), 
and 75 μL of NaOH (100 mM) were again added. After 
three cycles, the resulting particles were centrifuged 
at 1800  rpm for 20  min and re-dispersed in 10  mL of 
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15 mM aqueous solution of trisodium citrate, to remove 
any remaining interfering components.
Silver concentration of the as-prepared AgNP and 
Au@Ag nanoparticles was verified by atomic absorption 
spectroscopy. For this, nanoparticles were disrupted in 
a hydrogen-peroxide:sulfuric acid mixture using a CEM 
MARS 5 microwave digestion system. Ag concentration 
was determined in a Perkin Elmer Atomic absorption 
spectrometer using  AgNO3 standards.
The morphological characteristics of AgNPs, AuNPs 
and Au@Ag nanoparticles were investigated by transmis-
sion electron microscopy (TEM) using a FEI Tecnai  G2 20 
X-Twin microscope at an acceleration voltage of 200 kV. 
The particle size distribution of the samples was assessed 
by dynamic light scattering (DLS) analysis using a Zeta-
sizer Nano Instrument (Malvern, Worcestershire, UK). 
The optical properties of nanoparticles were studied by 
spectral analysis, and the absorbance spectra of nanopar-
ticles were recorded within the range from 300 to 800 nm 
using an Ocean Optics 355 DH-2000-BAL UV–VIS spec-
trophotometer and a 10-mm path length quartz cuvette.
Cell culture, assays and in vitro treatment conditions
All cell lines were purchased from ATCC and cultured 
under standard conditions. Briefly, 4T1 and MCF-7 
adenocarcinoma cells were maintained in RPMI supple-
mented with 10% FBS, 2 mM l-glutamine, 0.01% strepto-
mycin and 0.005% ampicillin, while NIH/3T3 fibroblasts 
were cultured in 4.5  g/L glucose DMEM supplemented 
with 10% FBS, 2  mM l-glutamine, 0.01% streptomycin 
and 0.005% ampicillin, respectively. MRC-5 human fibro-
blasts were maintained in EMEM complemented with 
10% FBS, 2  mM l-glutamine, 0.01% streptomycin and 
0.005% ampicillin.
Human patient-derived CAF cells were isolated from 
colon adenocarcinoma specimen resected at the Depart-
ment of Surgery, University of Szeged, Hungary. The 
study was performed in accordance with appropri-
ate guidelines and regulations, and the experimental 
protocols were all approved by the Human Investiga-
tion Review Board and Ethics Committee of the Albert 
Szent-Györgyi Medical and Pharmaceutical Centre at 
the University of Szeged (Ref#37/2006). The patient 
gave informed consent. For isolating fibroblast cells, 
the specimens were digested then cultured in selection 
RPMI medium supplemented with 10% FBS. When fibro-
blast cells reached confluence, cells were trypsinised and 
transferred to 10% FBS containing DMEM medium sup-
plemented with 1% amino acid solution. Primary fibro-
blasts used for the experiments were passaged no more 
than 4 times.
To determine  IC50 values, 10,000 cells were seeded 
into the wells of 96 well plates, then cells were treated 
with nanoparticles in various concentrations on the 
following day for 24  h. Cell viabilities were assessed 
using standard MTT assay described before [38]. Via-
bility values were expressed in the percentage of the 
untreated controls, then surviving curves and  IC50 val-
ues were determined using a GraphPad Prism 7.0 soft-
ware. Based on the  IC50 values, cells were treated with 
non-toxic nanoparticle concentrations (e. g. AuNP—
25  μM Au/0  μM Ag; AgNP—0  μM Au/20  μM Ag; 
Au@Ag—25 μM Au/20 μM Ag) for 24 h, upon further 
in vitro experiments.
To assess tumour cell migration, wound healing assays 
were performed. Cells were grown in 6 well plates until 
confluence, then each cell layer was scratched, creat-
ing crossing straight lines in the monolayer. Cell-free 
zones were photographed 0 and 24 h after scratching and 
wound healing activity was calculated using the follow-
ing formula (cell free area t0 − cell free area treatment 
time/cell free area t0 of control − cell free area t0 of con-
trol treatment time) × 100. In case of fibroblast migra-
tion tests, instead of measuring the cell-free area, the 
number of individual migrating cells was determined. At 
the end of the wound healing assays, cells were collected 
and stained with Annexin V/PI by following the instruc-
tions of the suppliers (Life Technologies). Fluorescent 
intensities of 10,000 events were determined using a BD 
FACScalibur flow cytometer, and raw data was analysed 
by FlowJo V10 software. Wound healing and migration 
experiments were repeated at least three times using 
three biological replicates. Statistical analysis was per-
formed using GraphPad Prism 7.0 software and repre-
sentative experiments are shown.
For LDH activity measurements, NIH/3T3 cells were 
seeded into 96 well plates in 2000 cells/well density, then 
were treated with nanoparticles on the following day. 
After 24 h treatments, Cytotoxicity LDH Assay Kit-WST 
(Dojindo) was applied and the instructions of the sup-
pliers were followed. Absorbance was read in a Synergy 
HTX multi-mode reader, and values were normalised to 
the positive control.
Transwell invasion assays were performed using the 
invasive 4T1 cell line. To do this, transwell inserts of 
0.33 cm2 area and 8 µm pore size (Corning) were coated 
with 20  μg Engelbreth-Holm-Swarm sarcoma extracel-
lular matrix gel (Sigma-Aldrich). 2.5 × 104  cells were 
seeded in 1% FBS and nanoparticle containing media 
onto the surface of the coated transwells, then 20% FBS 
containing medium was applied in the lower chambers 
as a chemoattractant. After 24  h, samples were fixed, 
stained with crystal violet and transmigrated cells were 
counted using a phase-contrast microscope. Transwell 
invasion experiments were repeated at least three times 
using three biological replicates. For statistical evaluation 
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GraphPad Prism 7.0 software was used and the results of 
one representative experiment are demonstrated.
PKH26 labelling and flow cytometry
4T1 cells were fluorescently labelled using the PKH26 
Red Fluorescent Linker Kit (Sigma-Aldrich). For this, 
5 million 4T1 cells were pelleted and stained by follow-
ing the instructions of the suppliers. Fluorescent 4T1 
cells were mixed with non-labelled NIH/3T3 fibroblasts 
in 1:1 ratio, then 1.5 × 105 cells were seeded into the wells 
of 6 well plates containing 1 cm diameter coverslips. Co-
cultures were treated with nanoparticles on the following 
day, then after 24 h treatments, coverslips were collected, 
cells were fixed with 4% PFA, then samples were visual-
ised under an Olympus BX51 fluorescent microscope. 
The remaining cells were trypsinised and fluorescent 
intensity of the sample was measured using BD FAC-
Scalibur flow cytometer. To identify labelled 4T1 cells 
and non-labelled NIH/3T3 cells, gating strategy was set 
according to dot plot profiles of fluorescently-labelled 
4T1 monocultures.
Animal studies
All the animal experimental protocols were approved 
and performed according guidelines and regulations of 
the Ethics Committee of the Biological Research Centre 
of the Hungarian Academy of Sciences and the Hun-
garian National Animal Experimentation and Ethics 
Board, in possession of an ethical clearance (number: 
XVI./1489/2014). 4T1-based tumour metastasis model 
has been applied as reported previously [39]. More pre-
cisely, for in vivo tumour growth, 100,000 4T1 cells were 
suspended in 100 µL RPMI and the cell suspensions were 
injected into the thoracic fat pad of 6–8 week old female 
Balb/c mice. When tumours became palpable, animals 
received nanoparticle treatments via peritumoural injec-
tions (V = 4 × 20 μL). Doses were the following: 4.8 μmol/
kg Ag upon AgNP and Au@Ag and 6 μmol/kg Au upon 
AuNP and Au@Ag treatments. Doxorubicin (Sigma) 
was applied intravenously in 4  mg/kg dose. Saline was 
used as administration control upon both peritumoural 
and intravenous injections. At the end of the treatment 
periods, animals were euthanised to perform necropsy. 
Tumours and vital organs were removed and measured, 
and lungs were photographed under a stereomicroscope 
to quantify metastatic nodules. Lung metastasis was fur-
ther quantified by calculating the weight of the meta-
static mass [metastatic mass (mg) = lung weight (mg) of 
tumour bearing mice − lung weight (mg) of healthy mice 
(2000  mg)], and by histopathology, where metastatic 
lesions were expressed as the percentage of the whole 
section area.
A standard toxicology experiment was also performed, 
in order to assess the systemic toxicity of Au@Ag nano-
particles upon the treatment period. To do this, 6–8 week 
old female Balb/c mice were divided into 3 groups (n = 3/
group), then animals received Au@Ag via intravenous 
injections four times in 6 μmol/kg dose.
Co‑culturing
For tumour cell—fibroblast co-cultures, NUNC Polycar-
bonate Cell Culture Inserts with 0.4  μm pore diameter 
and of 3.14 cm2 culture area were applied. 4T1 or MCF-7 
cells were cultured in the lower chambers of the 6 well 
plates, while NIH/3T3 or primary CAF cells were seeded 
on the surface of transwell inserts using the same cell 
density. When fibroblast cells reached confluence, inserts 
were transferred into the wells of the 4T1 cell contain-
ing 6 well plates. Tumour cells and fibroblasts were co-
cultured for 24 h, then the established cancer-associated 
fibroblast cells were treated with nanoparticles, while 
wound healing assay was performed on the 4T1 cells 
in the lower chamber. At the end of the experiments, 
NIH/3T3 and CAF cells were fixed, stained with crystal 
violet and visualized in a phase-contrast microscope, to 
ensure that the treatments did not induce the loss of cell–
cell junctions between fibroblasts.
Fibroblast conditioned media
To obtain fibroblast secreted factors, NIH/3T3 or pri-
mary CAF cells were treated for 24 h with nanoparticles, 
then nanoparticle containing media were replaced by 
fresh serum-free media. After 24  h incubation, condi-
tioned media were collected, concentrated with Amicon 
Ultra 4 K centrifugal filter devices, then protein concen-
trations of the obtained solutions were measured with 
BioRad Protein Assay.
BrdU incorporation assay
We measured the cell proliferation activity based on the 
S-phase-dependent incorporation of the nucleotide ana-
logue 5-bromo-2′-deoxyuridine (BrdU) using Cell pro-
liferation ELISA kit (Sigma-Aldrich). For this purpose, 
2000 cells were seeded into the wells of 96 well plates, on 
the following day cells were treated with fibroblast con-
ditioned media (containing fibroblast secreted proteins 
in 1 μg/mL concentration) for 24 h, then BrdU assay was 
performed following the instructions of the suppliers. 
Experiment was repeated three times using three bio-
logical replicates, and one representative experiment is 
shown.
RNA sequencing
To investigate transcriptomic changes upon nanoparticle 
treatments in cancer-associated fibroblasts, co-culture 
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experiments were performed. In the applied co-cul-
tures, 4T1 cells were grown on the surface of 3.14  cm2 
sized NUNC Polycarbonate Cell Culture Inserts, while 
NIH/3T3 cells were cultured below in the chambers of a 6 
well plate. After 24 h of co-culturing, fibroblast cells were 
selectively treated with nanoparticles for 24 h, then RNA 
was purified from the fibroblast cells by Qiagen RNeasy 
mini kit. RNA concentrations were measured in a Qubit 
2.0 fluorometer (Life Technologies), then RNA qualities 
were assessed in an Agilent 2100 Bioanalyzer by employ-
ing Agilent RNA 6000 nano Chip. Using 1 μg total RNA, 
non-strand specific sequencing library was prepared by 
Illumina TruSeq RNA sample Prep v2 kit, following the 
LS protocol. The size distribution of the generated library 
was assessed using DNA 1000 Chip in an Agilent 2100 
Bioanalyzer, then the sequencing library was quantified 
by applying NEBNext Library Quant Kit (New England 
BioLabs) in a PikoReal real-time PCR system. Following 
quantification, 2 × 75 paired-end sequencing was per-
formed on the samples using MiSeq Reagent kit V3-150 
in an Illumina MiSeq NGS platform.
Bioinformatics
Primary sequence analysis (base calling, demulti-
plexing, fastq file generation) was done by Run-Time 
Analysis (RTA v1.18.54) component of MiSeq Con-
trol Software (MSC v2.6.2.1). Fastq sequence files were 
quality trimmed and filtered to remove low quality and 
short sequences using Trimmomatic v0.33 in paired-
end mode using parameters TRAILING:10 SLIDING-
WINDOW:4:20 MINLEN:36. Paired sequence reads 
were aligned to GRCm38.p5 mouse reference genome 
(downloaded from https ://www.genco degen es.org) using 
TopHat 2.0. The resulting binary alignment (bam) files 
were sorted and deduplicated with SAMtools, then dif-
ferential gene expression analysis was done with Cuffdiff 
using a gene annotation file (gencode.vM12.annotation.
gtf ). Expression heatmap was visualised in RStudio using 
gplots and heatmap.plus packages. Using the expression 
data of significantly up- and downregulated genes and 
the online PANTHER statistical overrepresentation test, 
we performed gene ontology and PANTHER pathway 
analysis (https ://www.panth erdb.org). Upon the analy-
sis PANTHER GO-Slim Biological process was applied. 
Bonferroni correction was applied upon P-value calcu-
lation. Significant enrichments were considered when 
P ≤ 0.01. GraphPad Prism 7 software was used to repre-
sent P values in heat maps.
Clinical relevance of selected genes was demonstrated 
by the published survival data of patients with low or 
high expression profile of the given gene using the online 
tool available at https ://www.kmplo t.com [40]. Gene 
expression data of 196 TCGA patients was extracted by 
Rstudio software using FirebrowseR package. Only those 
patient data were included into the analyses where the 
vital status was indicated as “dead”.
Microarray data of metastatic 4T1 tumour sub-popula-
tions published by Tabariès et al. were obtained from the 
NCBI Gene Expression Omnibus Dataset Browser (https 
://www.ncbi.nlm.nih.gov/sites /GDSbr owser ?acc=GDS56 
66) [41]. Extracted gene expression and survival data was 
analysed using GraphPad Prism 7 software and P values 
were calculated with either log rank or unpaired t test.
Immunohistochemistry
3 randomly selected, formalin-fixed tissues from Saline- 
and Au@Ag-treated groups were routinely embedded in 
paraffin, then 4 mm thick paraffin slices were cut. Sam-
ples were deparaffinised, then heat-mediated antigen 
retrieval was performed using citrate buffer at pH = 6. 
Samples were blocked with donkey serum (Millipore) 
and stained with alphaSMA-specific antibody (1:200) 
(abcam, ab21027) then Alexa488-labelled donkey-anti-
goat secondary antibody (abcam, ab150129) was applied. 
After alphaSMA staining, samples were blocked again 
using normal goat serum, and Ki67-specific antibody 
(abcam, ab15580) was used in 1:50 dilution followed by 
Dylight549-labelled goat anti-rabbit secondary (abcam, 
ab96984). After immunoreactions, samples were coun-
terstained with DAPI and analysed by an Olympus BX51 
fluorescent microscope.
For correlation analysis, 4–5 photographs were taken 
from the subcutaneous regions of each tumour, then 
the percentage of alphaSMA- and Ki67-positive cells 
was quantified using CellProfiler 2.2.0 software. Statisti-
cal evaluation of the obtained data was performed using 
GraphPad Prism 7 software by calculating the Pearson r 
value.
Western blotting
3–3 randomly selected tumours from Saline and Au@
Ag-treated animals were sliced and homogenised in ice-
cold RIPA buffer supplemented with protease inhibitor 
cocktail (Calbiochem) using glass potter homogeniser. 
Homogenisation was facilitated by ultrasound sonica-
tion, and following centrifugation protein concentra-
tion of the supernatants obtained from each sample was 
determined using the BCA method. 10 μg total protein/
sample was resolved on 10% polyacrylamide-SDS gels, 
then transferred to nitrocellulose membranes (Amer-
sham). For the detection of Osteopontin, membranes 
were blocked with 5% BSA-TBST while 5% milk-TBST 
was used for alphaSMA, Vimentin and Tubulin detec-
tions. Primary antibodies were applied overnight (Anti-
Osteopontin (abcam, ab63856), Anti-alphaSMA (abcam, 
ab5694), Anti-Vimentin (abcam, ab8978), anti-Tubulin 
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times while black rectangles point the termination time of the experi-
ment. (b) Histopathology of the lungs of animals involved in the experi-
ment and used for morphometric analysis. 
Additional file 7. Number of surface metastatic nodules on the lungs 
of the animals involved in the second in vivo experiment. *P ≤ 0.05; 
**P ≤ 0.01 indicates statistical significance (unpaired t-test). 
Additional file 8. Intravenously administrated Au@Ag nanoparticles are 
not toxic in mice. To test the toxic effects of Au@Ag nanoparticles, 6–8 
week old female Balb/c mice were divided into 3 groups (n = 3), and 
left untreated, or received saline as an administration control or Au@Ag 
nanoparticles in four times (at day 1, day 5, day 9 and day 12) intrave-
nously. At day 20, animals were sacrificed and necroscopy was performed. 
Nanoparticle treatments did not influence the most important toxicology 
parameters as no differences were observed in the body, liver and spleen 
weights of the experimental animals between treated and control groups. 
Additional file 9. Characterisation of human primary CAF cells. Colon 
tumour samples were dissected and fibroblasts were isolated as described 
in Methods section. To validate that the isolated cells are fibroblasts, 
cultures were stained against CAF markers alphaSMA and Vimentin. 
Immunocytochemistry shows that the isolated primary cells are positive 
to both CAF markers, therefore are fibroblasts.  IC50 values were also estab-
lished on these cells after 24 h of AgNP and Au@Ag treatments.  IC50values 
are shown on the graph and expressed in M units. The obtained citotoxity 
profiles of AgNP and Au@Ag nanoparticles are comparable to those we 
observed on NIH/3T3 and MRC-5 cell lines. 
Additional file 10. LDH activity in the supernatant of nanoparticle 
treated NIH/3T3 cells. As none of the nanoparticle treatments triggered 
a measurable LDH activity in the supernatants, we concluded that these 
nanoparticles did not induce membrane damage upon the applied treat-
ment conditions. 
Additional file 11. Pre-treatment of fibroblast cells with AgNP or Au@Ag 
nanoparticles modifies their cancer cell proliferation-promoting activity. 
NIH/3T3 or primary CAF cells were treated with nanoparticles in non-toxic 
concentrations, then nanoparticle containing media was replaced 24 h 
later by serum free medium. Media were conditioned for 24 h, concen-
trated, and then applied on either 4T1 or MCF-7 adenocarcinoma cells. 
Exposures to supernatants of AgNP or Au@Ag-pre-treated fibroblasts led 
to diminished promotion of 4T1 and MCF-7 proliferations determined by 
BrdU incorporation tests. *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001; ****P ≤ 0.0001 
indicates statistical significance (unpaired t-test). 
Additional file 12. Proliferating tumour cells and cancer associated 
fibroblasts are found in the same microdomains of 4T1 tumours. Saline 
and Au@Ag treated tumour samples were PFA fixed, embedded to 
paraffin and immunohistochemistry was performed on deparaffinised 
sections using proliferation marker Ki67 and fibroblast marker alphaSMA 
specific antibodies. In the saline treated samples, high Ki67 density can be 
observed in the microenvironment of the fibroblast cells. In contrast with 
these, in the Au@Ag treated tumours, almost no proliferating cancer cells 
can be observed in the fibroblast-rich regions. 
Additional file 13. Percentage of alphaSMA and Ki67 positive cells in 
Saline and Au@Ag treated tumours. Au@Ag treatments did not modify 
the number of alphaSMA positive fibroblasts, but reduced significantly the 
number of Ki67 positive cells. ***P ≤ 0.001 indicates statistical significance 
(Unpaired t-test). 
Additional file 14. Similarities and differences between AgNP and Au@
Ag nanoparticle induced gene expressional changes in NIH/3T3 cells co-
cultured with 4T1 tumour cells. X-axis represent the expressional changes 
upon AgNP treatments, while Y-axis represents Au@Ag triggered expres-
sional changes. Both nanoparticle treatments induced primarily oxidative 
stress-response related genes, such as the Heme oxygenase 1 enzyme 
(Hmox1), or the antioxidant Metallothioneins (Mt1, Mt2). Interestingly, both 
treatments decreased the expression of the centrosomal protein CCDC28B 
(Ccdc28b). Only AgNP nanoparticle treatments upregulated the expression 
of the Acetoacetly-CoA Synthetase enzyme (Aacs) and the Transcription 
Elongation Factor A N-Terminal And Central Domain Containing 2 gene 
(Tceanc2) which is involved in ketone body metabolism and adipose tissue 
(Sigma, T9026), then membranes were incubated with 
HRP-conjugated secondary antibodies (DAKO). Mem-
branes were developed using ECL reagent (Immobilon) 
and the chemiluminescent signal was detected by a LI-
COR C-DiGit western blot scanner system. Uncropped 
western blots are presented in the Additional file 18.
Supplementary information
Supplementary information accompanies this paper at https ://doi.
org/10.1186/s1295 1-020-0576-x.
 Additional file 1.TEM, UV–Vis and DLS analysis of the obtained metal 
nanoparticles. TEM analysis of the as-prepared nanoparticles indicates that 
all the three nanoparticle preparations have quasi-spherical morphol-
ogy (a). UV–Vis analysis shows characteristic absorbance peak of AuNP 
at 530 nm wavelength. AgNP and Au@Ag nanoparticles have absorption 
maximum around 400 nm due to their characteristic surface plasmon 
resonance (b). DLS measurements indicate that AuNPs have a mean 
hydrodynamic diameter around 9 nm, while AgNPs are 12 nm and Au@Ag 
nanoparticle have 11 nm average diameter. DLS measurements indicate 
enlargement in size upon Au@Ag synthesis indicating the successful 
shell formation on the surface of the applied Au core particles. As the 
characteristic AuNP peak disappears in the UV–Vis spectrum of Au@Ag 
nanoparticles, we concluded that the silver coverage on the core surface 
is complete (c). Size distribution of the nanoparticles determined by TEM 
image analyses. Mean values are indicated in nm unit (d). 
Additional file 2. Surviving curves of AgNP and Au@Ag nanoparticle 
treated adenocarcinoma cells. Adenocarcinoma (4T1, MCF-7) and fibro-
blast (NIH/3T3, MRC-5) cells were seeded into 96 well plates, then were 
treated on the following day with various concentrations of AgNP and 
Au@Ag (a) or AuNP (b) nanoparticles. X-axis indicates the corresponding 
metal concentration of the medium upon nanoparticle treatments. MTT 
assay was performed 24 h after the addition of the nanoparticles and 
surviving curves were determined using GraphPad Prism 7.0 software.  IC50 
values were calculated and are indicated on the plots in M unit. 
Additional file 3. Nanoparticle treatments do not influence the migration 
activity of fibroblast cells. NIH/3T3 and MRC-5 fibroblasts were cultured in 
6 well plates until they reached confluency, then wounds were scratched 
and cells were treated with nanoparticles in the indicated metal concen-
trations. AgNP and AuNP nanoparticle concentrations were determined 
based on the silver and gold content of the medium upon Au@Ag 
nanoparticle treatments to selectively mimic the effects of the core and 
of the shell part of the Au@Ag nanoparticles. 24 h after treatments, cell 
free zones were photographed and numbers of migrating cells were 
determined. Nanoparticle treatments in the applied concentrations did 
not affect either NIH/3T3 or MRC-5 fibroblast migrations. 
Additional file 4. The inhibition of 4T1 and MCF-7 wound healing activity 
upon AgNP and Au@Ag nanoparticle treatments is not coupled to cyto-
toxicity. To verify that the observed inhibition of wound healing activity is 
not coupled to cytotoxicity, cells were collected after the wound healing 
assays, stained with Annexin V/PI and flow cytometry was performed 
to define the ratio, of early-, late-apoptotic and necrotic cells. Neither 
nanoparticles induced considerable apoptosis induction. As a positive 
control, tumour cells were pre-treated for 24 h with the well-characterised 
apoptosis inducer small molecule M627 in 10 M concentration. 
Additional file 5. Au@Ag nanoparticles suppress 4T1 tumour growth. 
Tumour progression curves of each animal involved in the experiment. 
Day 0 indicates the time of 4T1 tumour cell inoculation. Red rectangles 
indicate treatment times while black rectangles show termination time of 
the experiment. 
Additional file 6. Au@Ag alone and in combination with doxorubicin 
nanoparticles suppress metastasis in vivo. (a) Tumour progression curves 
of 4T1 tumours in every single animal involved in the experiment. Day 0 
indicates the inoculation of the cells. Red rectangles indicate treatment 
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development. Au@Ag nanoparticle treatments decreased the expression 
of the interferon-induced antiviral enzyme 2’-5’-oligoadenylate synthase-
like protein 2 (Oasl2), and the MMP-2 substrate cytokine Chemokine (C-C 
motif ) ligand 7 (Ccl7) which attracts macrophages during inflammation 
and metastasis. 
Additional file 15. Additional Table Significant alterations in the transcrip-
tome of cancer-associated fibroblast cells after AgNP, AuNP and Au@Ag 
treatments. 
Additional file 16. Kaplan–Meier plots of low and high expression levels 
of Ptn, Adamts5 and Thbs2 genes in breast cancer patients. 
Additional file 17. TCGA expression data of selected genes in normal and 
matching cancerous breast cancer tissues. 
Additional file 18. Uncropped version of western blots presented in 
Fig. 5.
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